The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Extended lab space for product development, customer demos, and training
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Changhua site meets international regulatory standards for global medical applications
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
